Categories AlphaGraphs, Health Care
Infographic: Abbott (ABT) reports Q2 2020 earnings
Weakness in medical devices unit hurt overall results in Q2
Abbott Laboratories (NYSE: ABT) reported second-quarter financial results before the regular trading hours on Thursday. Revenue for the quarter fell 8% to b $7.3 billion, while adjusted EPS declined 31% to $0.57.
However, the results were stronger than street projections, which sent the stock up 1% during pre-market hours. The stock has gained 11% since the beginning of this year.
The largest Medical Devices unit was the worst hit, where sales dropped 21%, as hospitals postponed various surgeries to cater to COVID patients. Earlier today, rival Johnson & Johnson (NYSE: JNJ) also reported a massive 35% decline in quarterly earnings, hurt by weakness in the medical devices segment.
Past performance
Also read: Abbott (ABT) could make a new 52-week high after upbeat Q2 results and rosier outlook
Most Popular
Netflix (NFLX): Four reasons why this leader will not be easy to overthrow
Netflix (NASDAQ: NFLX) has for long been the undisputed king of the streaming space. The streaming industry is seeing massive growth with several new players entering the field. It also
Fastenal (FAST) sees strong post-COVID prospects: Is the stock a buy?
The demand for services that involve minimal human interaction is on the rise as people continue to practice social distancing. Fastenal Co. (NASDAQ: FAST), a market-leading supplier of vending machines,
HEXO Corp. (HEXO) Earnings: 3Q21 Key Numbers
HEXO Corp. (NYSE: HEXO) reported its third-quarter 2021 earnings results today. Net revenue rose 2% year-over-year to CAD22.6 million. Net loss narrowed to CAD20.7 million from a loss of CAD19.5
